Marinus Prelims, ZTALMY® Net Product Revenue and Business Update

 

• ZTALMY® (ganaxolone) Q4 2023 preliminary net product revenue of between $6.5 and $6.7 million; full year 2023 preliminary net product revenue of between $19.5 and $19.7 million
• Projected full year 2024 U.S. ZTALMY net product revenue of between $32 and $34 million
• Over 90% of patients required for the interim analysis are now enrolled in the RAISE trial
• TrustTSC trial enrollment now over 70%; enrollment completion anticipated by end of Q1 and topline data anticipated in Q3 2024
• Cash runway projected into Q4 2024 with preliminary unaudited cash, cash equivalents and short-term investments of $150.3 million as of December 31, 2023

https://www.businesswire.com/news/home/20240104049645/en/